Ratings MorphoSys AG OTC Markets

Equities

MPSYF

DE0006632003

Market Closed - OTC Markets Other stock markets 09:30:02 2024-06-21 EDT			5-day change	1st Jan Change
72.38 ^USD	+1.40%		+1.40%	+76.54%

06-24	INDEX-MONITOR: Tui, Rational and Traton in the MDax - Douglas moves up to the SDax	DP
06-24	MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MORPHOSYS AG	+76.54%	2.73B	-
MODERNA, INC.	+38.36%	52.5B	B-
LONZA GROUP AG	+36.73%	39.31B	A
IQVIA HOLDINGS INC.	-8.63%	39.01B	B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	28.2B	B
CELLTRION, INC.	-11.17%	26.57B	C
ICON PUBLIC LIMITED COMPANY	+11.44%	26.2B	B-
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B	B+
MEDPACE HOLDINGS, INC.	+32.93%	12.62B	C+
BIO-TECHNE CORPORATION	-5.30%	11.74B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes